Lessons learned from the gene therapy trial for ornithine transcarbamylase deficiency
Level 5 - mechanism / opinion, no new human data
Expert commentary and narrative reflection without new empirical data
OpenAlex W2107496779 · doi:10.1016/j.ymgme.2008.12.016
What was done
The author, director of the institute that conducted the 1999 ornithine transcarbamylase deficiency (OTCD) liver gene therapy trial, provides retrospective reflections and lessons learned following the death of subject Jesse Gelsinger from vector administration complications.
What was found
No quantitative findings, sample statistics, or clinical metrics are reported in the abstract. The article is a narrative account and personal reflection on the trial events and their broader implications for translational medicine.
Why it matters
It offers first-person reflections from the principal investigator of a foundational safety event in human gene therapy that shaped contemporary regulatory, ethical, and clinical trial oversight standards.
Limits
This is a narrative essay and personal reflection (Oxford Level 5) rather than a primary clinical study or systematic review. It presents no new empirical data, controls, or formal statistical evaluations.
Cited by
- context An adenovirus gene therapy trial shut down the field of gene therapy in 1990 due to an adverse event.